These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 30226474)

  • 1. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
    Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB
    J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206.
    Chen X; Tan QQ; Tan XR; Li SJ; Zhang XX
    Cell Death Dis; 2021 Aug; 12(9):809. PubMed ID: 34446693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.
    Kim MH; Seong JB; Huh JW; Bae YC; Lee HS; Lee DS
    Redox Biol; 2020 Jan; 28():101315. PubMed ID: 31505325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.
    Zhao P; Saltiel AR
    J Biol Chem; 2020 Aug; 295(34):12279-12289. PubMed ID: 32651233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L; Fang K; Dan X; Gu M
    Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases.
    Sousa-Lima I; Kim HJ; Jones J; Kim YB
    Diabetes Metab J; 2021 Sep; 45(5):655-674. PubMed ID: 34610720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
    Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
    Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.
    Ye L; Cao Z; Lai X; Shi Y; Zhou N
    J Nutr; 2020 Apr; 150(4):672-684. PubMed ID: 31858105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-α signaling in obese mice.
    Diniz TA; de Lima Junior EA; Teixeira AA; Biondo LA; da Rocha LAF; Valadão IC; Silveira LS; Cabral-Santos C; de Souza CO; Rosa Neto JC
    Life Sci; 2021 Feb; 266():118868. PubMed ID: 33310034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis.
    Liu Y; Jiang L; Sun C; Ireland N; Shah YM; Liu Y; Rui L
    Nat Commun; 2018 Jul; 9(1):2751. PubMed ID: 30013137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice.
    Wang J; Chakrabarty S; Bui Q; Ruf W; Samad F
    Am J Pathol; 2015 Feb; 185(2):524-35. PubMed ID: 25476527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene.
    Zhao ZH; Wang ZX; Zhou D; Han Y; Ma F; Hu Z; Xin FZ; Liu XL; Ren TY; Zhang F; Xue Y; Cui A; Liu Z; Bai J; Liu Y; Cai G; Su W; Dai X; Shen F; Pan Q; Li Y; Fan JG
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):857-871. PubMed ID: 33989817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.